17 Harland CC, Goodfield MJD, Evans EGV. A follow up study of terbinafine Lamisil) Seventy seven patients had seen a doctor while they had the recognised symptoms of diabetes. In 42 there had been no reason to suspect a diagnosis ofdiabetes. In eight patients the diagnosis had been made a median of 13 (range 3-60) months previously, with findings of raised random blood glucose concentration in eight and glycosuria in seven, but the patients had not been informed. Seven of these patients had been seen in hospital departments. In 21 patients the diagnosis had been missed 6 (1-120) months before presentation. Of these, 12 had attended their general practice (3 with recurrent vaginal candidiasis, 1 with recurrent cellulitis, 8 with osmotic symptoms) and nine attended hospital departments (4 in ophthalmology (3 cataracts, 1 glaucoma), 2 in surgery (1 abscess, 1 "prostatism"), 2 in casualty (diabetic amyotrophy, recurrent abscess) and 1 in psychiatry). Urine had been tested in only one of these patients. Four patients had been informed of the diagnosis but failed to have further follow up for periods of 6-12 months before presentation. Thus, among 33 patients (43% of those who had seen a doctor) the potential for treatment had existed 9 (1-120) months previously and occurred at hospital departments in 16 patients, in general practice in 13, and after independent medical examinations in four.
Comment
Our data show that asymptomatic non-insulin dependent diabetes is unusual. Patients often have symptoms but do not recognise them as being abnormal. Almost 1154 BMJ VOLUME 304 40% of patients had symptoms for more than 12 months before starting treatment. Our previous study of the general public's knowledge of diabetes showed that fewer than one in 20 could name the combination of thirst and polyuria as symptoms, suggesting that poor levels of public health education for symptoms related to diabetes may have been an important cause of late presentation.5 Furthermore, earlier treatment might have been started in a third of our patients in whom the diagnosis either was made but not acted on or was overlooked. The results of this audit emphasise not only the need to raise awareness of diabetes among health professionals but also to increase the knowledge of major symptoms of diabetes by health promotion among the general public. The association between maternal serum haemolytic antibody concentration and outcome of pregnancy has been recognised from the 1950s and measurement of maternal anti-D antibody has been the traditional method of managing pregnancies in which red blood cell isoimmunisation has occurred. Fetal blood sampling from an umbilical cord vessel allows direct assessment of the severity of the disease by measurement of the haemoglobin concentration.' The aim of this study was to determine the association between maternal serum anti-D antibody concentration and fetal anaemia.
Patients, methods, and results
Fetal blood was obtained by fetoscopy2 (n=93) or cordocentesis3 (n= 144) from 237 pregnancies in which rhesus isoimmunisation had occurred at 17-38 weeks' gestation. The study was cross sectional, and the data were derived from fetuses that had not yet received transfusions. The In 19 pregnancies in which the fetus was not anaemic further maternal anti-D measurement and cordocentesis were performed two to three weeks subsequently. In the eight pregnancies in which the increase in maternal anti-D antibody was -15 IU/ml the fetuses remained at most mildly anaemic; in contrast, in six of the 11 pregnancies with an increase in maternal anti-D antibody > 15 IU/ml the fetus became moderately or severely anaemic (figure).
Comment
The significant association between the degree of fetal anaemia and maternal serum anti-D antibody concentration is compatible with the pathophysiology of rhesus disease, which involves the extravascular destruction of fetal red cells that are coated with transplacentally derived maternal anti-D antibody. In addition to intra-assay variation, the wide scatter of results may be due to individual variation in rate of transfer of antibody across the placenta, expression of antigens in fetal red cells, and fetal erythropoiesis in response to haemolysis.
In managing rhesus affected pregnancies cordocentesis gives accurate information on the severity of the disease and provides access for fetal intravascular blood transfusion.' 3 Even with experienced operators, however, the risk of fetal death from cordocentesis is about 1%. Furthermore, the procedure is commonly associated with fetomaternal haemorrhage and worsening of the disease.' If the maternal anti-D antibody concentration is 6 15 IU/ml the fetus is at most mildly anaemic, and therefore invasive antenatal intervention may not be indicated. In contrast, with a concentration
